REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.1 Prior to signing this Agreement, the Licensee has provided the NIH with the Commercial Development Plan in Appendix E, under which the Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.
Appears in 14 contracts
Samples: Patent License Agreement (Medicenna Therapeutics Corp.), Patent License Agreement (2seventy Bio, Inc.), Patent License Agreement (Aura Biosciences, Inc.)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.1 Prior to signing this Agreement, the Licensee has provided the NIH with the Commercial Development Plan in Appendix E, under which the Licensee intends to bring Licensed Product(s) or Licensed Process(es) within the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.
Appears in 4 contracts
Samples: Patent License Agreement (Bavarian Nordic a/S / ADR), Patent License Agreement (Bavarian Nordic a/S / ADR), Patent License Agreement (Lion Biotechnologies, Inc.)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.1 Prior to signing this Agreement, the Licensee has provided the NIH with the Commercial Development Plan in Appendix E, under which the Licensee intends to use Commercially Reasonable Efforts to bring Licensed Product(s) or Licensed Process(es) within the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.
Appears in 2 contracts
Samples: Patent License Agreement (Lion Biotechnologies, Inc.), Patent License Agreement (Lion Biotechnologies, Inc.)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.1 Prior to signing this Agreement, the Licensee has provided the NIH NIAID with the Commercial Development Plan in Appendix E, under which the Licensee intends to bring develop the subject matter Licensed Products or Licensed Processes with an intent of achieving the Practical Application of the Licensed Patent Rights to the point of Practical ApplicationRights. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.
Appears in 2 contracts
Samples: Agreement (Icosavax, Inc.), Agreement (Icosavax, Inc.)
